Scroll Top


Sponsorship Opportunities

The 56th Annual Scientific Meeting of the European Society for Paediatric Nephrology (ESPN) which will be held in Valencia from 23 to 27 September 2024, offers our industry partners several opportunities to reach a wide international audience working in the field of Paediatric Nephrology.

Starting from 2024, we have the pleasure to give to Companies the additional great chance to become an ESPN CORPORATE PARTNER, with a powerful commitment as significant associate for the Society and the Annual Meeting.

We also maintained a broad spectrum of sponsorship opportunities reserved exclusively to the Annual Meeting, for those sponsors which prefer to support only the Congress.

For more information on Sponsors & Exhibitors opportunity, please contact Sponsor& Exhibitor Department

Viale Giovine Italia, 17
50122 Florence – Italy
+39 055 50351
Fax +39 055 5001912

Platinum Sponsor

Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit


For more than 15 years, Advicenne has been dedicated to developing and providing innovative new treatments for people of all ages suffering from rare kidney diseases, with very few therapeutic options.
Through our expertise in drug reformulation and delivery, we make groundbreaking treatments. Sibnayal® (a combination of potassium citrate and potassium bicarbonate) has been approved in 2021 by the European Medicines Agency and the MHRA and is indicated for distal Renal Tubular Acidosis.
At Advicenne we are dedicated to improving the health of patients, and we are committed to enhance the quality of life for patients and their caregivers.

Alnylam is leading the translation of RNA interference into a whole class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious and central nervous system and ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for treating a wide range of severe, debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, MA.
Alnylam has funded the scientific medical educational part of the meeting only.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – our purpose is to make people smile, and we are united by our shared values of commitment to life, teamwork/Wa*, innovation, and integrity.

You can learn more about the business of Kyowa Kirin at:

*Harmony and loop among people

At Recordati Rare Diseases, we focus on the few – those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. Our global footprint will help ensure every patient we focus on has the opportunity to access our support and medicines.


Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease through the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 54,400 people in 80 countries, of which 3,300 work with rare diseases.

Travere Therapeutics is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies to people living with rare disease.
We come together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.